Generic Name and Formulations:
Epoprostenol (as sodium) 0.5mg, 1.5mg; per vial; pwd for IV infusion after reconstitution.
Primary pulmonary hypertension. Pulmonary hypertension due to scleroderma disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Give by continuous chronic IV infusion through a central venous catheter. Initially 2 nanograms/kg per min; increase in increments of 2 nanograms/kg per min at ≥15 minute intervals until response achieved or tolerance develops. Dose decreases should be made gradually in 2 nanograms/kg/min decrements at ≥15 minute intervals until dose-limiting effects resolve.
Chronic use with CHF due to severe left ventricular systolic dysfunction. Pulmonary edema.
Avoid abrupt withdrawal or large dose reductions (may cause rebound pulmonary hypertension). Bleeding disorders. Start anticoagulant therapy, unless contraindicated. Monitor BP and heart rate for several hours after dose changes. Pregnancy (Cat.B). Labor & delivery. Nursing mothers.
Potentiated hypotensive effects with diuretics, antihypertensive agents, other vasodilators. Potentiates anticoagulants, antiplatelet agents. May potentiate digoxin (monitor).
Headache, jaw pain, flushing, GI upset, flu-like symptoms, anxiety, dizziness, tachycardia, myalgia.
Vials—1 (w. diluent)
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...